GM-CSF Antibody (4G9): sc-32772
- GM-CSF Antibody (4G9) is a mouse monoclonal IgG1 provided at 200 µg/ml
- raised against mouse B cell lymphoma L1.2 transfectants expressing GM-CSF of human origin
- recommended for detection of GM-CSF of human origin by WB, IP and IF
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for GM-CSF Antibody (4G9). This work is in progress.
QUICK LINKS
SEE ALSO...
GM-CSF Antibody (4G9) is a mouse monoclonal IgG1 antibody that detects granulocyte-macrophage colony stimulating factor (GM-CSF) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). GM-CSF is a crucial pleiotropic cytokine that plays a significant role in the regulation of hematopoiesis, particularly in the proliferation and differentiation of granulocytes and macrophages. The mature form of GM-CSF consists of 127 amino acids, following the cleavage of a 17 amino acid signal peptide, and functions as a glycoprotein that can enhance the activity of various signaling pathways, including the phosphorylation of cytosolic phospholipase A2 (cPLA2) in human neutrophils. This phosphorylation is vital as GM-CSF can lead to increased enzyme activity, thereby influencing inflammatory responses and immune system regulation. Anti-GM-CSF antibody (4G9) serves as an essential tool for researchers studying GM-CSF′s role in immune responses and potential implications in various diseases, including autoimmune disorders and cancer.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
GM-CSF Antibody (4G9) References:
- GM-CSF-based cancer vaccines. | Dranoff, G. 2002. Immunol Rev. 188: 147-54. PMID: 12445288
- Targeting GM-CSF in inflammatory diseases. | Wicks, IP. and Roberts, AW. 2016. Nat Rev Rheumatol. 12: 37-48. PMID: 26633290
- Recent progress in GM-CSF-based cancer immunotherapy. | Yan, WL., et al. 2017. Immunotherapy. 9: 347-360. PMID: 28303764
- GM-CSF as a therapeutic target in autoimmune diseases. | Shiomi, A., et al. 2016. Inflamm Regen. 36: 8. PMID: 29259681
- GM-CSF: A Promising Target in Inflammation and Autoimmunity. | Lee, KMC., et al. 2020. Immunotargets Ther. 9: 225-240. PMID: 33150139
- GM-CSF: Orchestrating the Pulmonary Response to Infection. | McCormick, TS., et al. 2021. Front Pharmacol. 12: 735443. PMID: 35111042
- Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders. | Lazarus, HM., et al. 2022. Front Immunol. 13: 1069444. PMID: 36685591
- Anti-GM-CSF Neutralizing Autoantibodies in Colombian Patients with Disseminated Cryptococcosis. | Arango-Franco, CA., et al. 2023. J Clin Immunol. 43: 921-932. PMID: 36821021
- Role of GM-CSF in lung balance and disease. | Chen, Y., et al. 2023. Front Immunol. 14: 1158859. PMID: 37081870
- Intestinal stroma guides monocyte differentiation to macrophages through GM-CSF. | Kvedaraite, E., et al. 2024. Nat Commun. 15: 1752. PMID: 38409190
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GM-CSF Antibody (4G9) | sc-32772 | 200 µg/ml | $322.00 |